预约演示
Fierce Pharma Asia—BIO-WuXi break-off; Takeda's site closure; FDA's concern over Carvykti
基因疗法引进/卖出临床2期并购
The latest around the BIOSECURE Act, Takeda's plan to shut down a gene therapy facility, and an early death issue in Carvykti's clinical trial made our news this week.
WuXi AppTec left the Biotechnology Industry Organization amid increasing pressure on the trade group stemming from a draft U.S. bill targeting certain Chinese biotechs. Takeda will shut down a facility in Austria as the Japanese pharma pivots away from research in adeno-associated virus gene therapies. The FDA questioned whether Carvykti should be approved in earlier multiple myeloma after noticing an early detriment to patients' survival in a clinical trial. And more.
WuXi AppTectrade group pledges support for BIOSECURE Act, plans to boot member WuXi AppTecTakedaFDACarvyktiearlier multiple myeloma
The Biotechnology Industry Organization (BIO) is severing ties with WuXi AppTecWuXi AppTecthe “important steps” that the trade group is taking to support U.S. national security. In a revised statement, BIO said WuXi “proactively ended its membership.” BIO said it supports the BIOSECURE Act, which looks to block “adversary biotech companies,” including WuXi, from getting U.S. government contracts. BIO’s move came after its lobbying activity against the draft bill drew the ire of a lawmaker.
2. Takeda winds down manufacturing and R&D operations in Austria aftWuXi AppTecrapy pivot, plots 190 layoffs
TakTakeda shutting down operations at its adeno-associated virus gene therapy plant in Orth, Austria, and nearly 200 employees will lose their jobs. Takeda said it would divest the site about a year ago as part of its decision to end early R&D activities around AAV gene therapies. But after a “thorough and lengthy effort,” the company couldn’t find a buyer, a Takeda spokesperson said.
TheFDAA has raised concerns aCAR-T myelomaased risk ofJ&Jath for JohnsoCarvyktisoBristol MyersBiotech’s Carvykti compared with standard combinations in the first few months of its phase 3 trial in earlier lines of treatment for multiple myeloma. More patients in the Carvykti arm died than those in the control arm in the first 10 months of the CARTITUDE-4 trial. That overall survival data set is up for discussion during an FDA advisory committee meeting.
4. AFDAllas puts the cork back in $350M Xork deal after CartesianJohnson & JohnsonLegend BiotechCarvyktimultiple myelomaCarvyktiFDA
AstAstellass decided to end a licensing deal with Cartesian Therapeutics about a year after signing it originally with Selecta Biosciences. Under the deal, Astellas paid $10 million upfront to use Cartesian’s Xork, an immunoglobulin protease, with its gene therapy candidate AT845. The hope was that the asset would help more patients become eligible for adeno-associated virus-based gene therapies.
Astellasico 'pulls back the curtain' on AI drug diCartesian Therapeuticse of convincing skepticsSelecta BiosciencesAstellasCartesianimmunoglobulin proteaseAT845
In Insilico Biotechnology paper, Insilico Medicine described how it used artificial intelligence to discover, develop and test its lead candidate, INS018_055, a TNIK inhibitor that’s in phase 2 development for the lung disease idiopathic pulmonary fibrosis. The company’s AI platform, PandaOmics, was used to both identify a therapeutic target and to design a drug candidate.
6. Biocon continues to divest witInsilico Medicinensulin and other brands to ErisINS018_055TNIK inhibitorTNIKlung diseaseidiopathic pulmonary fibrosis
BioBiocons agreed to sell its Indian branded formulations business to Eris foErisout $150 million. The deal includes a portfolio of metabolic, oncology and critical care products, including Insugen, which was the first recombinant human insulin product developed domestically in India. The divested franchise accounted for 3.7% of Biocon’s revenue in its fiscal year 2023.
InnInnoventologics wiADCshut down its Rockville, Maryland, site, which serves as the Chinese firm’s U.S. headquarters and is conducting research in antibody-drug conjugates. A BioSpace article, citing former employees, reported that the R&D work will move to Chin and that the company has axed the entire research team at the Maryland location. But Innovent told Yicai that the lab will be relocated to California.
8. Chinese authorities rumored to be working on policies to support innovative drugs (Bloomberg)
9. Aurobindo unit begins shipping drugs from India plant after FDA inspection triggered production halt
10.Aurobindobumps AbbVie, J&J from top lymphoma event sponsor spot
12. Sun Pharmaa taps Mankind to goutribute Symbicort in India (The Economic Times)
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。